Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.

Robson JC, Dawson J, Doll H, Cronholm PF, Milman N, Kellom K, Ashdown S, Easley E, Gebhart D, Lanier G, Mills J, Peck J, Luqmani RA, Shea J, Tomasson G, Merkel PA.

Ann Rheum Dis. 2018 Aug;77(8):1157-1164. doi: 10.1136/annrheumdis-2017-212713. Epub 2018 Apr 25.

PMID:
29695498
2.

The European Vasculitis Society 2016 Meeting Report.

Bajema IM, Bruijn JA, Casian A, Cid MC, Csernok E, van Daalen E, Harper L, Hauser T, Little MA, Luqmani RA, Mahr A, Ponte C, Salama A, Segelmark M, Suzuki K, Sznajd J, Teng YKO, Vaglio A, Westman K, Jayne D.

Kidney Int Rep. 2017 Sep 21;2(6):1018-1031. doi: 10.1016/j.ekir.2017.09.008. eCollection 2017 Nov.

3.

Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure.

Robson JC, Dawson J, Cronholm PF, Milman N, Kellom KS, Ashdown S, Easley E, Farrar JT, Gebhart D, Lanier G, McAlear CA, Peck J, Luqmani RA, Shea JA, Tomasson G, Merkel PA.

Patient Relat Outcome Meas. 2018 Jan 4;9:17-34. doi: 10.2147/PROM.S144992. eCollection 2018.

4.

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Robson JC, Dawson J, Cronholm PF, Ashdown S, Easley E, Kellom KS, Gebhart D, Lanier G, Milman N, Peck J, Luqmani RA, Shea JA, Tomasson G, Merkel PA.

Rheumatol Int. 2018 Apr;38(4):675-682. doi: 10.1007/s00296-017-3855-6. Epub 2017 Nov 9.

5.

The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice.

Monti S, Floris A, Ponte CB, Schmidt WA, Diamantopoulos AP, Pereira C, Vaggers S, Luqmani RA.

Rheumatology (Oxford). 2018 Jan 1;57(1):112-119. doi: 10.1093/rheumatology/kex341.

PMID:
29045738
6.

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis.

Pearce FA, Craven A, Merkel PA, Luqmani RA, Watts RA.

Rheumatology (Oxford). 2017 Nov 1;56(11):1962-1969. doi: 10.1093/rheumatology/kex293.

PMID:
28968886
7.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

RMD Open. 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449. eCollection 2017.

8.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Robson JC, Tomasson G, Milman N, Ashdown S, Boonen A, Casey GC, Cronholm PF, Cuthbertson D, Dawson J, Direskeneli H, Easley E, Kermani TA, Farrar JT, Gebhart D, Lanier G, Luqmani RA, Mahr A, McAlear CA, Peck J, Shea B, Shea JA, Sreih AG, Tugwell PS, Merkel PA.

J Rheumatol. 2017 Oct;44(10):1529-1535. doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.

9.

Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?

Seeliger B, Sznajd J, Robson JC, Judge A, Craven A, Grayson PC, Suppiah RS, Watts RA, Merkel PA, Luqmani RA.

Rheumatology (Oxford). 2017 Jul 1;56(7):1154-1161. doi: 10.1093/rheumatology/kex075.

PMID:
28379475
10.

Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Morishita KA, Moorthy LN, Lubieniecka JM, Twilt M, Yeung RSM, Toth MB, Shenoi S, Ristic G, Nielsen SM, Luqmani RA, Li SC, Lee T, Lawson EF, Kostik MM, Klein-Gitelman M, Huber AM, Hersh AO, Foell D, Elder ME, Eberhard BA, Dancey P, Charuvanij S, Benseler SM, Cabral DA; ARChiVe Investigators Network within the PedVas Initiative.

Arthritis Rheumatol. 2017 Jul;69(7):1470-1479. doi: 10.1002/art.40112. Epub 2017 Jun 9.

11.

The association of vascular risk factors with visual loss in giant cell arteritis.

Yates M, MacGregor AJ, Robson J, Craven A, Merkel PA, Luqmani RA, Watts RA.

Rheumatology (Oxford). 2017 Apr 1;56(4):524-528. doi: 10.1093/rheumatology/kew397.

PMID:
27940595
12.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

13.

Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Robson JC, Milman N, Tomasson G, Dawson J, Cronholm PF, Kellom K, Shea J, Ashdown S, Boers M, Boonen A, Casey GC, Farrar JT, Gebhart D, Krischer J, Lanier G, McAlear CA, Peck J, Sreih AG, Tugwell PS, Luqmani RA, Merkel PA.

J Rheumatol. 2015 Nov;42(11):2204-9. doi: 10.3899/jrheum.141143. Epub 2015 Sep 1. Review.

14.

Giant cell arteritis: Current treatment and management.

Ponte C, Rodrigues AF, O'Neill L, Luqmani RA.

World J Clin Cases. 2015 Jun 16;3(6):484-94. doi: 10.12998/wjcc.v3.i6.484. Review.

15.

Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink.

Miller A, Nightingale AL, Sammon CJ, Mahtani KR, Holt TA, McHugh NJ, Luqmani RA.

Rheumatology (Oxford). 2015 Oct;54(10):1882-9. doi: 10.1093/rheumatology/kev131. Epub 2015 Jun 8.

PMID:
26060323
16.

Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink.

Sammon CJ, Miller A, Mahtani KR, Holt TA, McHugh NJ, Luqmani RA, Nightingale AL.

Pharmacoepidemiol Drug Saf. 2015 May;24(5):504-9. doi: 10.1002/pds.3750. Epub 2015 Mar 10.

PMID:
25758841
17.

Disease assessment in systemic vasculitis.

Luqmani RA.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i76-82. doi: 10.1093/ndt/gfv002. Epub 2015 Feb 5. Review.

PMID:
25662796
18.

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.

Ponte C, Sznajd J, O'Neill L, Luqmani RA.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-118-25. Epub 2014 Oct 30. Review.

PMID:
25365100
19.

State of the art in the treatment of systemic vasculitides.

Luqmani RA.

Front Immunol. 2014 Oct 13;5:471. doi: 10.3389/fimmu.2014.00471. eCollection 2014. Review.

20.

Vasculitis: an update.

Luqmani RA.

Br J Hosp Med (Lond). 2014 Aug;75(8):432-9. doi: 10.12968/hmed.2014.75.8.432. Review.

PMID:
25111094
21.

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Basu N, McClean A, Harper L, Amft EN, Dhaun N, Luqmani RA, Little MA, Jayne DR, Flossmann O, McLaren J, Kumar V, Erwig LP, Reid DM, Macfarlane GJ, Jones GT.

Rheumatology (Oxford). 2014 May;53(5):953-6. doi: 10.1093/rheumatology/ket483. Epub 2014 Jan 31.

PMID:
24489015
22.

Discontinuation of therapies in vasculitis.

Luqmani RA.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S93-7. Epub 2013 Oct 4.

PMID:
24129146
23.

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, Hamilton W, Emin A, Culliford D, Luqmani RA.

Ann Rheum Dis. 2015 Jan;74(1):129-35. doi: 10.1136/annrheumdis-2013-204113. Epub 2013 Oct 4.

PMID:
24095936
24.

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, Watts R, Merkel PA, Luqmani RA.

Clin Exp Nephrol. 2013 Oct;17(5):619-621. doi: 10.1007/s10157-013-0854-0. Epub 2013 Aug 31.

PMID:
23996327
25.

Explaining fatigue in ANCA-associated vasculitis.

Basu N, McClean A, Harper L, Amft EN, Dhaun N, Luqmani RA, Little MA, Jayne DR, Flossmann O, McLaren J, Kumar V, Erwig LP, Reid DM, Macfarlane GJ, Jones GT.

Rheumatology (Oxford). 2013 Sep;52(9):1680-5. doi: 10.1093/rheumatology/ket191. Epub 2013 Jun 4.

PMID:
23740186
26.

Is rheumatoid factor useful in primary care? A retrospective cross-sectional study.

Miller A, Mahtani KR, Waterfield MA, Timms A, Misbah SA, Luqmani RA.

Clin Rheumatol. 2013 Jul;32(7):1089-93. doi: 10.1007/s10067-013-2236-0. Epub 2013 Mar 21.

PMID:
23515604
27.

The characterisation and determinants of quality of life in ANCA associated vasculitis.

Basu N, McClean A, Harper L, Amft EN, Dhaun N, Luqmani RA, Little MA, Jayne DR, Flossmann O, McLaren J, Kumar V, Erwig LP, Reid DM, Jones GT, Macfarlane GJ.

Ann Rheum Dis. 2014 Jan;73(1):207-11. doi: 10.1136/annrheumdis-2012-202750. Epub 2013 Jan 25.

PMID:
23355077
28.

Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).

Dolezalova P, Price-Kuehne FE, Özen S, Benseler SM, Cabral DA, Anton J, Brunner J, Cimaz R, O'Neil KM, Wallace CA, Wilkinson N, Eleftheriou D, Demirkaya E, Böhm M, Krol P, Luqmani RA, Brogan PA.

Ann Rheum Dis. 2013 Oct;72(10):1628-33. doi: 10.1136/annrheumdis-2012-202111. Epub 2012 Oct 25.

PMID:
23100606
29.

The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target.

Chakera A, Bennett SC, Morteau O, Bowness P, Luqmani RA, Cornall RJ.

Clin Dev Immunol. 2012;2012:948218. doi: 10.1155/2012/948218. Epub 2012 Oct 4.

30.

Treat-to-target in vasculitis: is this a sensible approach?

Luqmani RA.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S149-53. Epub 2012 Oct 16.

PMID:
23079158
31.

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA.

Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715. No abstract available.

32.

Can we identify patients with microscopic polyangiitis who are at risk of relapse?

Luqmani RA.

J Rheumatol. 2012 Mar;39(3):455-7. doi: 10.3899/jrheum.111602. No abstract available.

PMID:
22383350
33.

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.

Suppiah R, Hadden RD, Batra R, Arden NK, Collins MP, Guillevin L, Jayne DR, Luqmani RA; European Vasculitis Study Group.

Rheumatology (Oxford). 2011 Dec;50(12):2214-22. doi: 10.1093/rheumatology/ker266. Epub 2011 Sep 2.

PMID:
21890618
34.

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, Suppiah R, Tomasson G, Luqmani RA.

J Rheumatol. 2011 Jul;38(7):1480-6. doi: 10.3899/jrheum.110276.

35.

Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, Luqmani RA, Neogi T, Seo P, Suppiah R, Tomasson G, Merkel PA.

J Rheumatol. 2011 Jul;38(7):1471-9. doi: 10.3899/jrheum.110275.

36.

Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS).

Luqmani RA, Suppiah R, Grayson PC, Merkel PA, Watts R.

Clin Exp Immunol. 2011 May;164 Suppl 1:11-3. doi: 10.1111/j.1365-2249.2011.04358.x. Review.

37.

An approach to the diagnosis and management of systemic vasculitis.

Miller A, Chan M, Wiik A, Misbah SA, Luqmani RA.

Clin Exp Immunol. 2010 May;160(2):143-60. doi: 10.1111/j.1365-2249.2009.04078.x. Epub 2010 Jan 12. Review.

38.

Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA.

Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi: 10.1136/ard.2008.101279. Epub 2008 Dec 3.

PMID:
19054820
39.

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.

Flossmann O, Baslund B, Bruchfeld A, Tervaert JW, Hall C, Heinzel P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DR.

Ann Rheum Dis. 2009 Jul;68(7):1125-30. doi: 10.1136/ard.2008.092429. Epub 2008 Aug 19.

PMID:
18713783
40.

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2008 Jul;67(7):1004-10. Epub 2007 Oct 2. Review.

41.

The future of damage assessment in vasculitis.

Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS, Jayne D, Kallenberg CG, Langford CA, Mahr A, Matteson EL, Mukhtyar CB, Neogi T, Rutgers A, Specks U, Stone JH, Ytterberg SR, Merkel PA.

J Rheumatol. 2007 Jun;34(6):1357-71.

PMID:
17552062
42.

Towards diagnostic criteria for the ANCA-associated vasculitides.

Luqmani RA.

Clin Exp Rheumatol. 2007 Jan-Feb;25(1 Suppl 44):S57. Review. No abstract available.

PMID:
17428369
43.

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA.

Ann Rheum Dis. 2007 May;66(5):605-17. Epub 2006 Dec 14. Review.

44.

Clinical and biological assessment in systemic necrotizing vasculitides.

Mukhtyar CB, Flossmann O, Luqmani RA.

Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S92-9. Review.

PMID:
16859602
45.

Outcome in small-vessel systemic vasculitis.

Luqmani RA, Flossmann O.

J Rheumatol. 2006 Jul;33(7):1224-7. No abstract available.

PMID:
16821262
46.

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Flossmann O, Jones RB, Jayne DR, Luqmani RA.

Ann Rheum Dis. 2006 Jul;65(7):841-4. Review. No abstract available.

47.

The role of biologic therapies in the management of systemic vasculitis.

Chan AT, Flossmann O, Mukhtyar C, Jayne DR, Luqmani RA.

Autoimmun Rev. 2006 Apr;5(4):273-8. Epub 2006 Feb 20. Review.

PMID:
16697969
48.

Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).

Deighton CM, George E, Kiely PD, Ledingham J, Luqmani RA, Scott DG.

Rheumatology (Oxford). 2006 Jun;45(6):649-52. Epub 2006 Mar 9. No abstract available.

PMID:
16527881
49.

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH; WGET Research Group.

Arthritis Rheum. 2005 Jul;52(7):2168-78.

50.

How to diagnose and treat secondary forms of vasculitis.

Luqmani RA, Pathare S, Kwok-Fai TL.

Best Pract Res Clin Rheumatol. 2005 Apr;19(2):321-36. Review.

PMID:
15857799

Supplemental Content

Loading ...
Support Center